Mercado mundial de pruebas farmacogenéticas en psiquiatría y depresión: tendencias de la industria y pronóstico hasta 2031

Personalice su informePersonalice su informe Compre ahoraCompre ahora Ejemplo de informe gratuitoEjemplo de informe gratuito
Hogar Medical Devices Global Pharmacogenetic Testing In Psychiatry Depression Market
Solicitud de índiceSolicitud de índice Hable con el analistaHable con el analista Comprar ahoraComprar ahora Consultar antes de comprarConsultar antes Informe de muestra gratuitoInforme de muestra gratuito

Mercado mundial de pruebas farmacogenéticas en psiquiatría y depresión: tendencias de la industria y pronóstico hasta 2031

  • Medical Devices
  • Published Report
  • Mar 2024
  • Global
  • 350 Páginas
  • Número de tablas: 977
  • Número de figuras: 48
Comprar ahoraComprar ahora

>Mercado mundial de pruebas farmacogenéticas en psiquiatría/depresión, por tipo (ansiedad, depresión, trastornos del estado de ánimo, trastornos bipolares, trastornos alimentarios y trastornos psicóticos), producto (consumibles, instrumentos, software y servicios), tipo de prueba (secuenciación del genoma completo y pruebas basadas en matrices cromosómicas), tipo de gen (CYP2C19, CYP2C9 y VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT y otros), tipo de paciente (adulto, geriátrico y niño), usuario final (hospital y clínicas, laboratorios de diagnóstico, institutos académicos y de investigación y otros), canal de distribución (licitación directa, distribución de terceros, farmacia hospitalaria y otros) - Tendencias de la industria y pronóstico hasta 2031.

Pruebas farmacogenéticas en el mercado de la psiquiatría y la depresión

Análisis y perspectivas del mercado de pruebas farmacogenéticas en psiquiatría y depresión

Se espera que el creciente número de pacientes que padecen trastornos psiquiátricos y depresivos impulse el crecimiento del mercado. La creciente demanda de medicina personalizada y de precisión está ayudando a impulsar el crecimiento del mercado. La falta de expertos médicos y genómicos capacitados y la falta de evidencia clínica sólida pueden obstaculizar el crecimiento del mercado. Sin embargo, se espera que los crecientes avances tecnológicos actúen como una oportunidad para el crecimiento del mercado.

Pruebas farmacogenéticas en el mercado de la psiquiatría y la depresión

Pruebas farmacogenéticas en el mercado de la psiquiatría y la depresión

Data Bridge Market Research analiza que se espera que el mercado global de pruebas farmacogenéticas en psiquiatría/depresión alcance los USD 2.66 mil millones para 2031 desde USD 1.22 mil millones en 2023, creciendo con una CAGR del 10,4% en el período de pronóstico de 2024 a 2031.

Métrica del informe

Detalles

Período de pronóstico

2024 a 2031

Año base

2023

Años históricos

2022 (personalizable para 2016-2021)

Unidades cuantitativas

Ingresos en miles de millones de USD y volumen en unidades

Segmentos cubiertos

Tipo (ansiedad, depresión, trastornos del estado de ánimo, trastornos bipolares, trastornos alimentarios y trastornos psicóticos), producto (consumibles, instrumentos, software y servicios), tipo de prueba (secuenciación del genoma completo y pruebas basadas en matrices cromosómicas), tipo de gen (CYP2C19, CYP2C9 y VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT y otros), tipo de paciente (adulto, geriátrico y niño), usuario final (hospital y clínicas, laboratorios de diagnóstico, institutos académicos y de investigación y otros), canal de distribución (licitación directa, distribución de terceros, farmacia hospitalaria y otros)

Países cubiertos

EE. UU., Canadá, México, Alemania, Reino Unido, Francia, Italia, Países Bajos, España, Rusia, Suiza, Turquía, Polonia, Noruega, Hungría, Austria, Irlanda, Lituania, Resto de Europa, China, Japón, India, Corea del Sur, Australia, Singapur, Tailandia, Indonesia, Malasia, Filipinas, Vietnam, Resto de Asia-Pacífico, Brasil, Argentina, Perú, Resto de Sudamérica, Arabia Saudita, Emiratos Árabes Unidos, Israel, Sudáfrica, Egipto y Resto de Medio Oriente y África.

Actores del mercado cubiertos

Thermo Fisher Scientific Inc., Illumina Inc., Myriad Genetics Inc., Sonic Healthcare Limited, QIAGEN, AB-BIOTICS SA, BiogeniQ Inc., Castle Bioscience Inc., Coriell Life Sciences, Dynamic DNA Laboratories, Eurofins Scientific, Genelex, Genewiz, Genomind Inc., GenXys, HealthSpek, HudsonAlpha, MD Labs, ONEOME LLC y PacBio, entre otros.

Definición de mercado

Las pruebas farmacogenéticas estudian la interacción entre el fármaco y la respuesta genética de una persona y buscan la variación genética responsable de influir en el efecto del fármaco. La prueba está ganando mucha demanda, ya que muchos investigadores y científicos han identificado la interacción única entre los fármacos y los genes individuales y proporciona información valiosa que posteriormente se puede utilizar para desarrollar medicamentos personalizados.

Dinámica del mercado de las pruebas farmacogenéticas en psiquiatría y depresión

En esta sección se aborda la comprensión de los factores impulsores, las oportunidades, las limitaciones y los desafíos del mercado. Todo esto se analiza en detalle a continuación:     

Conductores

  • Aumenta el número de personas que padecen trastorno depresivo

La depresión es una enfermedad muy extendida en todo el mundo que varía de cambios de humor normales a cambios de humor normales. Puede convertirse en un problema de salud grave, de gravedad leve a extrema, que hace que la persona sufra mucho y puede llevar al suicidio en los peores casos. Si bien hay más de 45 antidepresivos disponibles, la respuesta subóptima plantea dificultades y se considera que es resultado de la variación genética.

Con la creciente prevalencia de la depresión, también está aumentando la demanda de pruebas farmacogenéticas, ya que estudian el efecto de las variantes genéticas para brindar un tratamiento personalizado, lo que está impulsando el crecimiento del mercado.

  • El sector de la biotecnología crece junto con el aumento del gasto sanitario

Las personas son cada vez más conscientes de su salud y también están más alertas a la necesidad de una atención sanitaria preventiva. El énfasis en la atención sanitaria está ganando popularidad. El conocimiento de las enfermedades y los síntomas es esencial para la detección temprana de enfermedades gracias a la tecnología avanzada disponible en el sistema sanitario, como las pruebas avanzadas que ayudan a los proveedores de atención sanitaria y conducen a tasas de supervivencia más altas.

Se prevé que el creciente sector de la biotecnología, junto con el aumento del gasto sanitario a nivel mundial, impulse el mercado de las pruebas farmacogenéticas en los campos de la psiquiatría y la depresión. Existe un mayor interés en la medicina personalizada, incluidas las pruebas farmacogenéticas, a medida que las empresas de biotecnología desarrollan métodos y tecnologías de prueba innovadores. Esto, combinado con el aumento del gasto sanitario, indica una creciente inversión en soluciones sanitarias avanzadas que podrían mejorar los resultados de los pacientes y reducir los costes sanitarios generales, lo que está impulsando el crecimiento del mercado.

Pruebas farmacogenéticas en el mercado de la psiquiatría y la depresión

Oportunidad

  • Avances en las pruebas genéticas

The field of healthcare is experiencing rapid technological advancements, particularly in the development of new and sophisticated methods to promote pharmacogenetics testing. These innovative tests utilize advanced genetic testing methods to provide precise results, enabling healthcare providers to tailor treatment regimens more effectively. This advancement presents a significant opportunity for the global pharmacogenetics testing market in psychiatry and depression. As these cutting-edge technologies become more accessible and refined, they have the potential to revolutionize personalized medicine, offering patients more targeted and effective treatments for mental health conditions.

These tests play a crucial role in establishing a meaningful connection between a drug and an individual's genetic profile. This personalized approach aids healthcare providers in selecting the most suitable medications for patients suffering from major depressive disorders and other psychiatric conditions. By leveraging advancements in genetic testing, pharmacogenetics testing can significantly enhance treatment outcomes and improve patient care in psychiatry and depression, which is expected to create an opportunity for market growth.

Restraints/Challenges

  • Insufficient Clinical Validation

With advancements in medical sciences, new testing methods are being increasingly developed to come up with potent drugs that are efficient in treating major depressive disorders. The antidepressants and the antipsychotics used in the treatments can be ineffective. They can help in suggesting the drugs that can be used to treat the disease as per individual patient needs.

Even though having such an advantage, the tests lack a strong clinical basis to completely rely on them. Although studies conducted on small populations have shown promising results, the efficacy of the tests has no evidence on the larger population.

The pharmacogenetics testing in psychiatry does not assess for non-compliance in treatment outcomes. As a result, when the rate of non-adherence increases in the population being considered, the power of the statistics lowers leading to a lack of evidence to prove the efficiency of the tests.

The lack of basis to entirely depend on these tests is a major drawback in the market. The patients would prefer to stick to traditional methods of testing and thus, it is hindering the market growth.

  • Rising Concern Regarding Data Privacy and Security

Pharmacogenetic testing, which analyzes how an individual's genetic makeup influences their response to medications, raises significant concerns about data privacy and security, particularly in the context of global data sharing and storage. Genetic information is inherently personal and can reveal sensitive details about an individual health, including predispositions to certain diseases and responses to specific drugs. As such, there is a heightened risk of this information being misused or improperly accessed if not adequately protected.

A major concern is the risk of genetic discrimination, where individuals could experience negative outcomes in employment or insurance due to their genetic information. Data breaches are another significant risk, particularly as genetic information is increasingly shared across borders for research or clinical purposes. The transfer of data between jurisdictions with differing privacy regulations can further complicate efforts to ensure data security.

Data privacy and security stand out as significant challenges for the global implementation of pharmacogenetic testing in the psychiatry depression market due to the sensitive nature of genetic information, there is a potential risk of misuse or unauthorized access of patients data which they have provided. The sensitive nature of the data can give rise to several issues, which are expected to challenge the market growth.

Recent Developments

  • In February 2024, Myriad Genetics, Inc., a pioneer in genetic testing and precision medicine, has acquired select assets from Intermountain Health's Precision Genomics (IPG) laboratory. This includes the Precise Tumor Test, the Precise Liquid Test, and IPG's CLIA-certified laboratory in St. George, Utah. This acquisition allows Myriad to enhance its tumor profiling offerings and expand its oncology portfolio, which includes hereditary cancer and companion diagnostic testing options
  • In February 2024, QIAGEN announced that it has been recognized for its sustainability efforts by My Green Lab, a non-profit organization focused on promoting sustainability in scientific research. This will enhance QIAGEN's reputation for sustainability, potentially attracting environmentally conscious customers and partners
  • In November 2023, QIAGEN and DNA Labs International collaborated to solve two decades-old cold cases using QIAGEN's ForenSeq Kintelligence System for forensic genetic genealogy, in conjunction with the GEDmatch PRO database. This highlights the effectiveness and increasing adoption of this approach to human identification. This will result in the effectiveness of QIAGEN's forensic genetic genealogy solutions, potentially boosting their adoption and sales in the forensic market
  • In June 2022, Castle Biosciences, Inc, a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire AltheaDx, Inc. This acquisition would enable to potentially develop a mental health franchise, starting with a test that currently receives Medicare reimbursement for depression
  • In May 2022, Coriell Life Sciences won Second MedTech Breakthrough Award for Genomics Innovation which leads the way in unlocking the power of pharmacogenomics to improve healthcare. the organization’s Corigen Medication Safety Program has been named “Best Overall Genomics Solution” in the 2022 MedTech Breakthrough Awards. The award will give the testing more credibility among the users

Global Pharmacogenetics Testing in Psychiatry/Depression Market Scope

The global pharmacogenetics testing in psychiatry/depression market is segmented into seven notable segments based on type, product, test type, gene type, patient type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.

Type

  • Anxiety
  • Depression
  • Mood Disorders
  • Bipolar Disorders
  • Eating Disorders
  • Psychotic Disorders

On the basis of type, the global pharmacogenetics testing in psychiatry/depression market is segmented into anxiety, depression, mood disorders, bipolar disorders, eating disorders, and psychotic disorders.

Product

  • Consumables
  • Instruments
  • Software and Services

On the basis of product, the global pharmacogenetics testing in psychiatry/depression market is segmented into consumables, instruments, and software and services.

Test Type

  • Whole Genome Sequencing
  • Chromosomal Array Based Tests

On the basis of test type, the global pharmacogenetics testing in psychiatry/depression market is segmented into whole genome sequencing and chromosomal array based tests.

Gene Type

  • CYP2C19
  • CYP2C9 and VKORC1
  • CYP2D6
  • HLA-B
  • HTR2A/C
  • HLA-A
  • CYP3A4
  • SLC6A4
  • MTHFR
  • COMT
  • Others

On the basis of gene type, the global pharmacogenetics testing in psychiatry/depression market is segmented into CYP2C19, CYP2C9 and VKORC1, CYP2D6, HLA-B, HTR2A/C, HLA-A, CYP3A4, SLC6A4, MTHFR, COMT, and others.

Patient Type

  • Adult
  • Geriatric
  • Child

On the basis of patient type, the global pharmacogenetics testing in psychiatry/depression market is segmented into adult, geriatric, and child.

End User

  • Hospital and Clinics
  • Diagnostics Laboratories
  • Academic and Research Institutes
  • Others

On the basis of end user, the global pharmacogenetics testing in psychiatry/depression market is segmented into hospital and clinics, diagnostics laboratories, academic and research institutes, and others.

Distribution Channel

  • Direct Tender
  • Third Party Distribution
  • Hospital Pharmacy
  • Others

On the basis of distribution channel, the global pharmacogenetics testing in psychiatry/depression market is segmented into direct tender, third party distribution, hospital pharmacy, and others.

Pruebas farmacogenéticas en el mercado de la psiquiatría y la depresión

Global Pharmacogenetics Testing in Psychiatry/Depression Market Regional Analysis/Insights

The global pharmacogenetics testing in psychiatry/depression market is segmented into seven notable segments based on type, product, test type, gene type, patient type, end user, and distribution channel.

The countries covered in this market report are U.S., Canada, Mexico, Germany, U.K., France, Italy, Netherlands, Spain, Russia, Switzerland, Turkey, Poland, Norway, Hungary, Austria, Ireland, Lithuania, rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Indonesia, Malaysia, Philippines, Vietnam, rest of Asia-Pacific, Brazil, Argentina, Peru, rest of South America, Saudi Arabia, U.A.E., Israel, South Africa, Egypt, and rest of Middle East and Africa.

North America is expected to dominate the global pharmacogenetics testing in psychiatry/depression market as increasing number of population suffering from depressive disorder in the region. The U.S. is expected to dominate the North America region because robust initiatives taken by manufacturers due to genetic variability. China is expected to dominate the Asia-Pacific region due to the growing biotechnology sector along with rising healthcare expenditure. Germany is expected to dominate the Europe region due to increasing interest for personalized and precision medication.

The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.

Pruebas farmacogenéticas en el mercado de la psiquiatría y la depresión

Global Pharmacogenetics Testing in Psychiatry/Depression Market Competitive Landscape and Share Analysis

The global pharmacogenetics testing in psychiatry/depression market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breadth, application dominance, and product type lifeline curve. The above data points provided are only related to the company’s focus on the global pharmacogenetics testing in psychiatry/depression market.

Algunos de los principales actores que operan en el mercado son Thermo Fisher Scientific Inc., Illumina Inc., Myriad Genetics Inc., Sonic Healthcare Limited, QIAGEN, AB-BIOTICS SA, BiogeniQ Inc., Castle Bioscience Inc., Coriell Life Sciences, Dynamic DNA Laboratories, Eurofins Scientific, Genelex, Genewiz, Genomind Inc., GenXys, HealthSpek, HudsonAlpha, MD Labs, ONEOME LLC y PacBio, entre otros.

SKU-

Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo

Sample Image Click on image to enlarge
  • Panel de análisis de datos interactivo
  • Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
  • Acceso de analista de investigación para personalización y consultas
  • Análisis de la competencia con panel interactivo
  • Últimas noticias, actualizaciones y análisis de tendencias
  • Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Solicitud de demostración

Tabla de contenido

  1. introduction
    1. OBJECTIVES OF THE STUDY
    2. MARKET DEFINITION
    3. OVERVIEW of Global pharmacogenetic testing in psychiatry/depression market
    4. LIMITATIONs
    5. MARKETS COVERED
  2. MARKET SEGMENTATION
    1. MARKETS COVERED
    2. geographical scope
    3. years considered for the study
    4. currency and pricing
    5. DBMR TRIPOD DATA VALIDATION MODEL
    6. MULTIVARIATE MODELLING
    7. type LIFELINE CURVE
    8. primary interviews with key opinion leaders
    9. DBMR MARKET POSITION GRID
    10. market application coverage grid
    11. vendor share analysis
    12. secondary sourcEs
    13. assumptions
  3. EXECUTIVE SUMMARY
  4. premium insights
  5. REGULATIONS: GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET
    1. UNITED STATES
      1. ROLE OF FDA
      2. ROLE OF CDC AND HCFA
    2. EUROPEAN UNION
    3. FRANCE
    4. AUSTRALIA
    5. SOUTH KOREA
  6. market overview
    1. drivers
      1. RISING NUMBER OF POPULATION SUFFERING FROM DEPRESSIVE DISORDER
      2. INITIATIVES TAKEN BY MANUFACTURERS
      3. GROWING BIOTECHNOLOGY SECTOR ALONG WITH RISING HEALTHCARE EXPENDITURE
      4. INCREASING INTEREST FOR PERSONALIZED AND PRECISION MEDICATION
      5. GROWING MEDICAL TOURISM
    2. RESTRAINTS
      1. LACK OF STRONG CLINICAL EVIDENCE
      2. HIGH COST
      3. LACK OF REIMBURSEMENT
    3. OPPORTUNITIES
      1. TECHNOLOGICAL ADVANCEMENTS
      2. EMERGENCE OF NEW PLAYERS
      3. Untapped market
    4. CHALLENGES
      1. STRINGENT GOVERNMENT REGULATION
      2. SHORTAGE OF SKILLED PERSONNEL
  7. COVID-19 IMPACT ON GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET
    1. IMPACT ON PRICE
    2. IMPACT ON DEMAND
    3. IMPACT ON SUPPLY
    4. KEY INITIATIVES BY MARKET PLAYER DURING COVID 19
    5. CONCLUSION:
  8. GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE
    1. overview
    2. WHOLE GENOME SEQUENCING
    3. array-based TESTS
  9. GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES
    1. overview
    2. cyp2c19
    3. CYP2C9 and VKORC1
    4. cyp2d6
    5. HLA-B
    6. htr2a/c
    7. HLA-A
    8. cyp3A4
    9. slc6a4
    10. MTHFR
    11. COMT
    12. others
  10. GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE
    1. overview
    2. PRESCRIPTION DRUGS
    3. Over-the-counter medications
    4. RECREATIONAL DRUGS
    5. VITAMINS/NUTRACEUTICals
  11. GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE
    1. overview
    2. SALIVA
    3. BLOOD
  12. GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY application
    1. overview
    2. DRUG DEVELOPMENT
    3. CLINICAL PRACTICE
  13. GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER
    1. overview
    2. pharmaceutical and biotechnology companies
    3. HEALTHCARE PROVIDERS
    4. research centers and academic institues
    5. others
  14. GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL
    1. overview
    2. RETAIL PHARMACIES
    3. HOSPITAL PHARMACIES
    4. MAIL-ORDER PHARMACIES
    5. DIRECt-to-customer services
  15. GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, by Geography
    1. overview
    2. north america
      1. u.s.
      2. canada
      3. mexico
    3. europe
      1. u.k.
      2. germany
      3. france
      4. italy
      5. spain
      6. netherlands
      7. belgium
      8. russia
      9. switzerland
      10. turkey
      11. rest of europe
    4. Asia-Pacific
      1. JAPAN
      2. cHINA
      3. SOUTH KOREA
      4. INDIA
      5. AUSTRALIA
      6. SINGAPORE
      7. THAILAND
      8. MALAYSIA
      9. indonesia
      10. philipPines
      11. rest of asia-pacific
    5. south america
      1. BRAZIL
      2. argentina
      3. rest of south america
    6. middle east & africa
      1. south africa
      2. saudi arabia
      3. uae
      4. israel
      5. egypt
      6. rest of middle east & africa
  16. Global Pharmacogenetic Testing in psychiatry/depression Market: COMPANY landscape
    1. company share analysis: Global
    2. company share analysis: North America
    3. company share analysis: Europe
    4. company share analysis: Asia-Pacific
  17. swot analysis
  18. company profile
    1. MYRIAD GENETICS, INC.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. Company share analysis
      4. PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENTS
    2. THERMO FISHER SCIENTIFIC INC.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. Company share analysis
      4. PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENT
    3. STADA ARZNEIMITTEL AG
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. Company share analysis
      4. PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENTS
    4. sonic healthcare
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. Company share analysis
      4. PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENT
    5. Illumina, Inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. Company share analysis
      4. PRODUCT PORTFOLIO
      5. RECENT DEVELOPMENTS
    6. AB-Biotics, S.A.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. 6.3 PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    7. ALTHEADX
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    8. biogeniq inc.
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    9. Color
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    10. cnsdose
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    11. CORIELL LIFE SCIENCES
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    12. Dynamic DNA Laboratories
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    13. GENELEX
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    14. genomind, inc.
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    15. genxys
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    16. HEALTHSPEK
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    17. HudsonAlpha Health Alliance (A Division of HudsonAlpha)
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    18. luminex corporation
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    19. MILLENNIUM HEALTH
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    20. mydna life australia pty ltd.
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    21. oneome
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    22. OMECARE
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    23. PerkinElmer Inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    24. R-Biopharm AG
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
  19. questionnaire
  20. related reports

Lista de Tablas

TABLE 1 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY TYPE, (2021-2028)(USD Million)

TABLE 2 Global Whole Genome Sequencing in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 3 Global Array-Based Tests in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 4 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY GENES, (2021-2028)(USD Million)

TABLE 5 Global CYP2C19 in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 6 Global CYP2C9 AND VKORC1 in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 7 Global CYP2D6 in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 8 Global HLA-B in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 9 Global HTR2A/C in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 10 Global HLA-A in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 11 Global CYP3A4 in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 12 Global SLC6A4 in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 13 Global MTHFR in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 14 Global COMT in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 15 Global Others in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 16 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DRUG TYPE, (2021-2028)(USD Million)

TABLE 17 Global PRESCRIPTION DRUGS in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 18 Global OVER-THE-COUNTER MEDICATIONS in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 19 Global RECREATIONAL DRUGS in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 20 Global VITAMINS/NUTRACEUTICALS in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 21 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY SAMPLE TYPE, (2021-2028)(USD Million)

TABLE 22 Global Saliva in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 23 Global blood in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 24 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY APPLICATION, (2021-2028)(USD Million)

TABLE 25 Global Drug Development in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 26 Global Clinical Practice in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 27 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY END USER, (2021-2028)(USD Million)

TABLE 28 Global Pharmaceutical & Biotechnology Companies in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 29 Global Healthcare Providers in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 30 Global Research Centres And Academic Institutes in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 31 Global Others in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 32 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY DISTRIBUTION CHANNEL, (2021-2028)(USD Million)

TABLE 33 Global Retail Pharmacies in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 34 Global Hospital Pharmacies in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 35 Global Mail-Order Pharmacies in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million))

TABLE 36 Global Direct-To-Customer Services in Pharmacogenetic Testing in psychiatry/depression Market, By Region, 2019-2028 (USD Million)

TABLE 37 Global Pharmacogenetic Testing in psychiatry/depression Market , By Region, 2021-2028 (USD Million)

TABLE 38 north america pharmacogenetic testing in psychiatry/depression Market, By COUNTRY, 2021-2028 (USD million)

TABLE 39 north america pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 40 north america pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 41 north america pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 42 north america pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 43 north america pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 44 north america pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 45 north america pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 46 u.s. pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 47 u.s. pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 48 u.s. pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 49 u.s. pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 50 u.s. pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 51 u.s. pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 52 u.s. pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 53 canada pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 54 canada pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 55 canada pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 56 canada pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 57 canada pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 58 canada pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 59 canada pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 60 mexico pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 61 mexico pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 62 mexico pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 63 mexico pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 64 mexico pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 65 mexico pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 66 mexico pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 67 europe pharmacogenetic testing in psychiatry/depression Market, By COUNTRY, 2021-2028 (USD million)

TABLE 68 europe pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 69 europe pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 70 europe pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 71 europe pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 72 europe pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 73 europe pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 74 europe pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 75 u.k. pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 76 u.k. pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 77 u.k. pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 78 u.k. pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 79 u.k. pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 80 u.k. pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 81 u.k. pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 82 germany pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 83 germany pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 84 germany pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 85 germany pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 86 germany pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 87 germany pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 88 germany pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 89 france pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 90 france pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 91 france pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 92 france pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 93 france pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 94 france pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 95 france pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 96 italy pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 97 italy pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 98 italy pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 99 italy pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 100 italy pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 101 italy pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 102 italy pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 103 spain pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 104 spain pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 105 spain pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 106 spain pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 107 spain pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 108 spain pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 109 spain pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 110 netherlands pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 111 netherlands pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 112 netherlands pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 113 netherlands pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 114 netherlands pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 115 netherlands pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 116 netherlands pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 117 belgium pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 118 belgium pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 119 belgium pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 120 belgium pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 121 belgium pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 122 belgium pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 123 belgium pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 124 russia pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 125 russia pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 126 russia pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 127 russia pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 128 russia pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 129 russia pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 130 russia pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 131 switzerland pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 132 switzerland pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 133 switzerland pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 134 switzerland pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 135 switzerland pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 136 switzerland pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 137 switzerland pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 138 turkey pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 139 turkey pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 140 turkey pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 141 turkey pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 142 turkey pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 143 turkey pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 144 turkey pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 145 rest of europe pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 146 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, BY COUNTRY, 2018-2028 (USD MILLION)

TABLE 147 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 148 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)

TABLE 149 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)

TABLE 150 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)

TABLE 151 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)

TABLE 152 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)

TABLE 153 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)

TABLE 154 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 155 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)

TABLE 156 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)

TABLE 157 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)

TABLE 158 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)

TABLE 159 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)

TABLE 160 JAPAN PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)

TABLE 161 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 162 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)

TABLE 163 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)

TABLE 164 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)

TABLE 165 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)

TABLE 166 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)

TABLE 167 CHINA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)

TABLE 168 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 169 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)

TABLE 170 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)

TABLE 171 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)

TABLE 172 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)

TABLE 173 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)

TABLE 174 SOUTH KOREA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)

TABLE 175 India PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 176 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)

TABLE 177 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)

TABLE 178 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)

TABLE 179 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)

TABLE 180 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)

TABLE 181 INDIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)

TABLE 182 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 183 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)

TABLE 184 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)

TABLE 185 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)

TABLE 186 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)

TABLE 187 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)

TABLE 188 australia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)

TABLE 189 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 190 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)

TABLE 191 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)

TABLE 192 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)

TABLE 193 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)

TABLE 194 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)

TABLE 195 SINGAPORE PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)

TABLE 196 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 197 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)

TABLE 198 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)

TABLE 199 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)

TABLE 200 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)

TABLE 201 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)

TABLE 202 THailand PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)

TABLE 203 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 204 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)

TABLE 205 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)

TABLE 206 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)

TABLE 207 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)

TABLE 208 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)

TABLE 209 MALAYSIA PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)

TABLE 210 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 211 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)

TABLE 212 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)

TABLE 213 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)

TABLE 214 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)

TABLE 215 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)

TABLE 216 indonesia PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)

TABLE 217 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 218 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By GENE, 2021-2028 (USD Million)

TABLE 219 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DRUG Type, 2021-2028 (USD Million)

TABLE 220 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By SAMPLE TYPE, 2021-2028 (USD Million)

TABLE 221 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By APPLICATION, 2021-2028 (USD Million)

TABLE 222 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By END USER, 2021-2028 (USD Million)

TABLE 223 PHILIPPINES PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By DISTRIBUTION CHANNEL, 2021-2028 (USD Million)

TABLE 224 Rest of Asia-Pacific PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET, By Type, 2021-2028 (USD Million)

TABLE 225 south america pharmacogenetic testing in psychiatry/depression Market, By COUNTRY, 2021-2028 (USD million)

TABLE 226 south america pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 227 south america pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 228 south america pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 229 south america pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 230 south america pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 231 south america pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 232 south america pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 233 brazil pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 234 brazil pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 235 brazil pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 236 brazil pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 237 brazil pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 238 brazil pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 239 brazil pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 240 argentina pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 241 argentina pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 242 argentina harmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 243 argentina pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 244 argentina pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 245 argentina pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 246 argentina pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 247 rest of south america pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 248 middle east & africa pharmacogenetic testing in psychiatry/depression Market, By COUNTRY, 2021-2028 (USD million)

TABLE 249 middle east & africa pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 250 middle east & africa pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 251 middle east & africa pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 252 middle east & africa pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 253 middle east & africa pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 254 middle east & africa pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 255 middle east & africa pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 256 south africa pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 257 south africa pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 258 south africa pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 259 south africa pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 260 south africa pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 261 south africa pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 262 south africa pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 263 saudi arabia pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 264 saudi arabia pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 265 saudi arabia pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 266 saudi arabia pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 267 saudi arabia pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 268 saudi arabia pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 269 saudi arabia pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 270 uae pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 271 uae pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 272 uae pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 273 uae pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 274 uae pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 275 uae pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 276 uae pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 277 israel pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 278 israel pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 279 israel pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 280 israel pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 281 israel pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 282 israel pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 283 israel pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 284 egypt pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

TABLE 285 egypt pharmacogenetic testing in psychiatry/depression Market, By genes, 2021-2028 (USD million)

TABLE 286 egypt pharmacogenetic testing in psychiatry/depression Market, By drug type, 2021-2028 (USD million)

TABLE 287 egypt pharmacogenetic testing in psychiatry/depression Market, By sample, 2021-2028 (USD million)

TABLE 288 EGYPT pharmacogenetic testing in psychiatry/depression Market, By application, 2021-2028 (USD million)

TABLE 289 egypt pharmacogenetic testing in psychiatry/depression Market, By end user, 2021-2028 (USD million)

TABLE 290 egypt pharmacogenetic testing in psychiatry/depression Market, By distribution channel, 2021-2028 (USD million)

TABLE 291 rest of middle east & africa pharmacogenetic testing in psychiatry/depression Market, By type, 2021-2028 (USD million)

Lista de figuras

FIGURE 1 Global PHARMACOGENTIC TESTIG IN PSYCHIATRY/DEPRESSION market: segmentation

FIGURE 2 Global PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION market: data triangulation

FIGURE 3 Global PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION market: DROC ANALYSIS

FIGURE 4 Global PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION market: global vs REGIONAL MARKET ANALYSIS

FIGURE 5 Global PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION market: COMPANY RESEARCH ANALYSIS

FIGURE 6 Global PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION market: INTERVIEW DEMOGRAPHICS

FIGURE 7 Global PHARMACOGENETIC TESTING IN PSYCHIATRIC/DEPRESSION market: DBMR MARKET POSITION GRID

FIGURE 8 GLOBAL pharmacogenetic testing in psychiatry/depression MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 9 Global pharmacogenetic testing in psychiatry/depression market: vendor share analysis

FIGURE 10 Global pharmacogenetic testing in psychiatry/depression market: SEGMENTATION

FIGURE 11 initiatives taken by manufacturers is expected to drive THE Global pharmacogenetic testing in psychiatry/depression market IN THE FORECAST PERIOD of 2021 to 2028

FIGURE 12 whole genome sequencing segment is expected to account for the largest share of the Global pharmacogenetic testing in psychiatry/depression market in 2021 & 2028

FIGURE 13 NORTH AMERICA is expected to DOMINATE the gLOBAL pharmacogenetic testing in psychiatry/depression market and ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028

FIGURE 14 asia-pacific is the fastest growing market for pharmacogenetic testing in psychiatry/depression manufacturers in the forecast period of 2021 to 2028

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET

FIGURE 16 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, 2021-2028

FIGURE 17 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, 2021-2028 (USD MILLION)

FIGURE 18 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, CAGR (2021-2028)

FIGURE 19 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY TYPE, LIFELINE CURVE

FIGURE 20 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, 2021-2028

FIGURE 21 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, 2021-2028 (USD MILLION)

FIGURE 22 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, CAGR (2021-2028)

FIGURE 23 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY GENES, LIFELINE CURVE

FIGURE 24 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, 2021-2028

FIGURE 25 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, 2021-2028 (USD MILLION)

FIGURE 26 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, CAGR (2021-2028)

FIGURE 27 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 28 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY SAMPLE TYPE, 2021-2028

FIGURE 29 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY SAMPLE TYPE, 2021-2028 (USD MILLION)

FIGURE 30 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DRUG TYPE, CAGR (2021-2028)

FIGURE 31 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY SAMPLE TYPE, LIFELINE CURVE

FIGURE 32 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, 2021-2028

FIGURE 33 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, 2021-2028 (USD MILLION)

FIGURE 34 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, CAGR (2021-2028)

FIGURE 35 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY APPLICATION, LIFELINE CURVE

FIGURE 36 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, 2021-2028

FIGURE 37 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, 2021-2028 (USD MILLION)

FIGURE 38 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, CAGR (2021-2028)

FIGURE 39 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY END USER, LIFELINE CURVE

FIGURE 40 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, 2021-2028

FIGURE 41 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)

FIGURE 42 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)

FIGURE 43 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 44 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)

FIGURE 45 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY Region (2020)

FIGURE 46 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY Region (2021 & 2028)

FIGURE 47 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY Region (2020 & 2028)

FIGURE 48 GLOBAL PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY type (2021-2028)

FIGURE 49 north america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)

FIGURE 50 north america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020)

FIGURE 51 north america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2021 & 2028)

FIGURE 52 north america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020 & 2028)

FIGURE 53 north america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY type (2021-2028)

FIGURE 54 europe PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)

FIGURE 55 europe PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020)

FIGURE 56 europe PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2021 & 2028)

FIGURE 57 europe PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020 & 2028)

FIGURE 58 europe PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY type (2021-2028)

FIGURE 59 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)

FIGURE 60 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020)

FIGURE 61 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2021 & 2028)

FIGURE 62 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020 & 2028)

FIGURE 63 ASIA-PACIFIC PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY type (2021-2028)

FIGURE 64 south america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)

FIGURE 65 south america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020)

FIGURE 66 south america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2021 & 2028)

FIGURE 67 south america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020 & 2028)

FIGURE 68 south america PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY type (2021-2028)

FIGURE 69 middle east & africa PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: SNAPSHOT (2020)

FIGURE 70 middle east & africa PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020)

FIGURE 71 middle east & africa PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2021 & 2028)

FIGURE 72 middle east & africa PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY COUNTRY (2020 & 2028)

FIGURE 73 middle east & africa PHARMACOGENETIC TESTING IN PSYCHIATRY/DEPRESSION MARKET: BY type (2021-2028)

FIGURE 74 Global Pharmacogenetic testing in psychiatry/depression Market: company share 2020 (%)

FIGURE 75 North America pharmacogenetic testing in psychiatry/depression Market: company share 2020 (%)

FIGURE 76 Europe pharmacogenetic testing in psychiatry/depression Market: company share 2020 (%)

FIGURE 77 Asia-Pacific pharmacogenetic testing in psychiatry/DEPRESSION MARKET: company share 2020 (%)

Ver información detallada Right Arrow

Metodología de investigación

La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.

La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.

Personalización disponible

Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados ​​en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.

Preguntas frecuentes

The major players in the Pharmacogenetics Testing in Psychiatry/Depression Market are Genelex (Part of Invitae corporation), Genewiz (Part of Azenta Life Sciences), MD Labs, BiogeneiQ, Inc., ONEOME, LLC, Myriad Genetics, Inc., GenXys, Castle Biosciences, Inc., PacBio, QIAGEN, etc.
The Pharmacogenetics Testing in Psychiatry/Depression Market growth rate is 10.4% during the forecast period.
The Pharmacogenetics Testing in Psychiatry/Depression Market growth rate is USD 2.66 billion by 2031 during the forecast period.
The type, product, test type, gene type, patient type, end user, and distribution channel are the factors on which the Pharmacogenetics Testing in Psychiatry/Depression Market research is based.
The latest developments in the Pharmacogenetics Testing in Psychiatry/Depression Market are Myriad Genetics, Inc., a pioneer in genetic testing and precision medicine, has acquired select assets from Intermountain Health's Precision Genomics (IPG) laboratory and QIAGEN announced that it has been recognized for its sustainability efforts by My Green Lab, a non-profit organization focused on promoting sustainability in scientific research.

Explorar páginas relacionadas

Banner